Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by JayjayUSA12007on Jun 27, 2018 10:46pm
190 Views
Post# 28242148

Convertible vs Share price: the inverse relationship

Convertible vs Share price: the inverse relationship
While Thera share price went down, the convert price went up:
https://www.stockhouse.com/companies/quote/t.th.db.u/theratechnologies

On the other hand, someone on this board raised the question (and doubt) regarding the theory that buyers of the convert were short-selling the shares for risk management. The poster posits that it would make no sense why they short-sell at $C11-12 to cover 4 years later at $C19.xx .
Well, it makes sense if one think this way:
1/ They would cover at any points there will be a firm indication of Tregarzo sales taking off as a blockbuster. These people would know well ahead of the market !
2/ These buyers, collectively, handed Thera $57 million for $3.x million annual interest for 4 years. Would anyone guarantee Thera will pay them back this money (with interest, of course), given these notes are unsecured ?
What if Thera went BK ? What if Trogarzo sales were less than desirable and SP went down ?
They would likely lose the whole $57 million in that BK case !
Now, if they short the stock at $12, they would be able to hold on to 63% of their capital, even in the event of a unlikely Thera BK. This percentage is likely computed with their actuary formula using the likelyhood/probability of a Thera BK.

In short, in all scenario ranging from the worst (BK) to a failed Trogarzo, to a successful blockbuster Trogarzo, this Risk management strategy would cover them all.

That would explain this shorting activity during the last several weeks.
Bullboard Posts